Resuscitating Cancer Immunosurveillance: Selective Stimulation of DLL1-Notch Signaling in T cells Rescues T-cell Function and Inhibits Tumor Growth

Yuhui Huang¹, Luping Lin¹, Anil Shanker¹-², Anshu Malhotra², Li Yang¹, Mikhail M. Dikov¹, and David P. Carbone¹

Abstract

Deficiencies in immune function that accumulate during cancer immunoediting lead to a progressive escape from host immunosurveillance. Therapies that correct or overcome these defects could have a powerful impact on cancer management, but current knowledge of the types and mechanisms of immune escape is still incomplete. Here, we report a novel mechanism of escape from T-cell immunity that is caused by reduction in levels of the Delta family Notch ligands DLL1 and DLL4 in hematopoietic microenvironments. An important mediator of this effect was an elevation in the levels of circulating VEGF. Selective activation of the DLL1-Notch signaling pathway in bone marrow precursors enhanced T-cell activation and inhibited tumor growth. Conversely, tumor growth led to inhibition of Delta family ligand signaling through Notch in the hematopoietic environment, resulting in suppressed T-cell function. Overall, our findings uncover a novel mechanism of tumoral immune escape and suggest that a soluble multivalent form of DLL1 may offer a generalized therapeutic intervention to stimulate T-cell immunity and suppress tumor growth. Cancer Res; 71(19); 1–10. ©2011 AACR.

Introduction

Immunotherapy theoretically can specifically eliminate malignant cells with low toxicity. Unfortunately, although hints of activity have been observed, clinical immunotherapy efforts have proven largely ineffective to date (1, 2). We now recognize that at least part of this failure is due to the numerous immunoregulatory circuits influenced by cancers, which alter the differentiation and function of bone marrow–derived immune cells, including T cells. Both the Notch and VEGF signaling pathways are well known to regulate the function and differentiation of immune cells, but the interplay of these two and the therapeutic implications of this finding in cancer are poorly understood.

In mice, Notch signaling consists of 4 receptors (Notch1–Notch4), 2 serrate-like ligands (Jagged1, Jagged2), and 3 Delta-like ligands (DLL1, DLL3, and DLL4; refs. 3, 4). DLL4 and VEGF are both genes in which loss of a single allele results in embryonic lethality due to failure to form a functional vasculature (5, 6). This fact provides genetic evidence for the importance of both VEGF and Notch signaling pathways in vascular development. Many other studies have shown the interplay of Notch and VEGF in angiogenesis (7). VEGF induces DLL4 ligand expression in tumor blood vessels (8, 9), and subsequent DLL4-mediated Notch signaling regulates the differentiation and proliferation of endothelial cells responsive to VEGF and thereby promotes the timely formation of a functional and well-organized vascular network (7).

In addition, Notch and VEGF signaling also plays essential roles in immune cell development and differentiation. Inactivation of Notch1 signaling results in impairment of T lymphopoiesis accompanied by promotion of B-cell development (10, 11). Conversely, retroviral transduction of bone marrow precursors with the Notch1 intracellular domain results in phopoiesis accompanied by promotion of B-cell development (10, 11). Delta-like family ligands also play critical roles in T lymphopoiesis. Overexpression of Delta1 or Delta4 in bone marrow precursors in vivo, or expression of DLL1 or DLL4 in stromal cells in vitro, leads to induction of T-cell development and suppression of B-cell development (14–19). A recent study further shows that DLL4 is the essential and nonredundant Notch1 ligand responsible for T-cell lineage commitment (20). One important feature of Delta-like family ligands is that they act in a dose/density-dependent manner (5, 18, 21). Higher density of Delta1 promotes T-cell development and inhibits B-cell development, whereas relatively lower density of Delta1 promotes development of both T and B cells (22). The gain and loss of function studies clearly show that Notch signaling is necessary and sufficient for T- versus B-lineage commitment and that both DLL1 and DLL4 can modulate T-cell development (3, 4).
VEGF and its receptors (VEGFR) are also widely expressed in the hematopoietic system and regulate hematopoiesis (6). In tumor-bearing hosts, elevated levels of VEGF affect the differentiation and maturation of immune cells, including T cells, and thus contribute to cancer-associated immunodeficiency (23–26). However, little is known about the interplay between Notch and VEGF signaling pathways in the immune system and specifically in cancer-associated immunosuppression.

Here, we show that tumor growth downregulates expression of DLL1 and DLL4 in the hematopoietic environment and elevated circulating VEGF is one causative factor. Selective stimulation of DLL1-Notch signaling rescues the observed tumor-associated T-cell alterations and dramatically slows tumor growth. Thus, this study suggests the novel concept that stimulation of DLL1-Notch signaling may be an effective strategy to overcome tumor-associated T-cell immunosuppression.

Materials and Methods

Cell lines

The murine Lewis lung carcinoma (LLC) cell line was obtained from the American Type Culture Collection less than 6 months ago. D459 cells are murine fibroblasts malignant transformed in our laboratory by transfection of 

ras

and

p53

(27). Thus, our laboratory is the primary source of these cells, and we regularly go back to reference stocks to ensure fidelity. No other identity testing was done; only routine sterility and mycoplasma testing were done.

Mice

Female Balb/c, C57BL/6, and

Rag1

mice (6- to 8-week-old) were purchased from Harlan and The Jackson Laboratory, respectively. The animals were housed in pathogen-free units at Vanderbilt University School of Medicine, in compliance with Institutional Animal Care and Use Committee regulations. Balb/c mice were inoculated s.c. with D459 (murine fibrosarcoma). C57BL/6 and

Rag1

mice were inoculated s.c. with LLC cells.

Reagents

DC101, a rat-neutralizing monoclonal antibody specifically against mouse VEGFR-2, was a generous gift from ImClone system. The matched control antibody rat IgG was purchased against mouse VEGFR-2, was a generous gift from ImClone.

EGF administration

VEGF

and its mutants (KDR-sel and Flt-sel) were generous gifts from Genentech Inc. (28). Osmotic pumps were purchased from ALZET.

Quantitative RT-PCR in cancer patient samples

We collected de-identified excess archived paraffin-embedded bone marrow samples resected for clinical indications from lung cancer patients without bone marrow metastases before any treatment (4 squamous cell carcinoma, 3 adenocarcinoma, 1 transitional cell carcinoma, and 1 large cell carcinoma). We used de-identified archived excess bone marrow samples from femurs of age-matched individuals undergoing clinically indicated hip replacement as controls. We extracted RNA from formalin-fixed paraffin-embedded (FFPE) bone marrow samples by FFPE RNA isolation kit (Ambion) and used a set of specific primers described earlier (30) to analyze the transcription of Delta1 and Hes1 in bone marrow.

Bone marrow transduction and transplantation

Retroviral constructs MigR1-DLL1 and Mig-R1 were generous gifts from Sunnybrook and Women's College Health Science Centre, Toronto, Ontario, Canada (17). Retroviral supernatants were generated using the Bosc23 packaging cell line. Bone marrow cells were infected with retrovirus as previously described (12, 14).

Enzyme-linked immunosorbent spot assay

Mice were inoculated s.c. with D459 tumor cells. Tumor volumes were assessed by bilateral Vernier caliper measurement every 3 days and calculated by the formula [length × (width)²]/2. IFN-γ-producing T cells were measured by enzyme-linked immunosorbent spot (ELISPOT) assays according to the manufacturer's instructions (Becton Dickinson). Briefly, splenocytes (2 × 10⁶ per well) were added in triplicate on anti-mouse IFN-γ precoated 96-well plates and stimulated with anti-CD3 and anti-CD28 at 37°C in a 5% CO₂ humidified incubator overnight. The IFN-γ-secreting T cells were enumerated using a CTL ImmunoSpot analyzer (Cellular Technology Limited) and the supporting ImmunoSpot Software. Spots were counted by an automated system using a defined set of parameters for size, intensity, and gradient.

Soluble clustered DLL1 treatment and CD8⁺ T-cell depletion in vivo

DLL1-Fc fusion protein is composed of the extracellular domain of mouse DLL1 and the Fc part of mouse IgG2A. To form clustered DLL1, DLL1-Fc, biotinylated donkey anti-mouse IgG antibodies (all from R&D Systems), and NeutrAvidin (Pierce) were mixed at a molar ratio of 1:4:10 in PBS (50 mg/mL DLL1-Fc, 335 μg/mL anti-mouse IgG antibodies, and 335 μg/mL NeutrAvidin) and incubated at room temperature for 15 to 30 minutes. As a control in all applications, Fc fragment of mouse IgG2 (Sigma) was used instead of DLL1-Fc. Six- to 8-week-old C57BL/6,

Rag1

mice, and Balb/c mice were inoculated s.c. with 0.5 × 10⁶ LLC cells and 0.3 × 10⁶ D459 tumor cells, respectively. Starting the same day, C57BL/6 mice were treated with 10 units/kg of DC101, a rat-neutralizing monoclonal antibody specifically for De-identified excess archived paraffin-embedded bone marrow samples resected for clinical indications...
with clustered DLL1, receiving 2.4 μg of DLL1-Fc protein in 100 μL of PBS intraperitoneally daily, and Balb/c mice were treated with clustered DLL1, receiving 5 μg of DLL1-Fc protein in 100 μL of PBS intraperitoneally every other day. The control group received control clusters with Fc fragments only. In some groups of mice, purified anti-mouse CD8a antibody (clone 53-6.7; BioLegend) or isotype-matched IgG antibody was administered intraperitoneally at a dose of 100 μg on days −1, 0, 7, 14, and 21 with respect to the day of tumor injection. Tumor volume was measured with calipers.

Western blotting
Proteins were extracted from splenocytes, separated by 10% SDS-PAGE, and transferred to nitrocellulose membranes (Amersham Biosciences). Antibodies to DLL1 or DLL4 (sc-9102 or sc-18641; Santa Cruz Biotechnology) were used. Protein content was normalized using mouse monoclonal anti-β-actin (Sigma) or anti-mouse glyceraldehydes-3-phosphate dehydrogenase (GAPDH; sc-25778; Santa Cruz Biotechnology).

Flow cytometric analysis
Fresh single-cell suspensions of red blood cell–depleted splenocytes, bone marrow cells, or thymocytes (1 × 10^6 cells) were incubated with monoclonal antibodies in the dark on ice for 30 minutes. Flow cytometric data were acquired with a FACSCalibur flow cytometer (Becton Dickinson) and analyzed by WinList 5.0. Matched fluorochrome-conjugated isotype IgG controls were used in all experiments. Monoclonal antibodies used were CD19-PE, CD3e-FITC, B220/CD45R-PerCP, CD3e-PerCP, CD4-FITC, CD8a-PE, CD3e-biotin, CD4-biotin, CD45-biotin, CD43-PE, streptavidin-PerCP, and streptavidin-APC (Becton Dickinson).

Statistical analysis
Results were presented as mean ± SEM. Unpaired 2-tailed Student t test was used to analyze the difference between 2 groups. Values were considered statistically significant when P was less than 0.05.

Results
Tumor-derived factors attenuate the levels of Delta ligands in the bone marrow of cancer patients and tumor-bearing animals
Notch signaling is highly dose- and context-dependent and plays diverse roles in cancer (31). DLL1 and DLL4 are 2 critical Notch ligands involved in T-cell development and tumor angiogenesis (4, 7). We studied the transcriptional levels of Delta1 (a Notch ligand) and Hes1 (a Notch target gene) in the bone marrow of cancer patients and found them to be present at reduced levels compared with those from tumor-free donors (Fig. 1A), suggesting that tumors can attenuate Notch signaling in the bone marrow microenvironment. Consistent
with this observation, the transcriptional levels of DLL1 and DLL4 were also significantly decreased in bone marrow cells from tumor-bearing mice (Fig. 1B). Expression of DLL1 and DLL4 protein was also dramatically decreased in splenocytes from tumor-bearing mice (Supplementary Fig. S1). We then sought to determine the functional consequences of these alterations.

**Overexpressing DLL1 alone in bone marrow precursors significantly improves T-cell immune responses and inhibits tumor growth**

To examine the effect of alterations in DLL1 expression in the hematopoietic environment on tumor growth, we transduced bone marrow precursors with a DLL1-carrying retrovirus (Mig-DLL1) or a control retrovirus (MigR1), both of which also express a green fluorescent protein (GFP) marker (Supplementary Fig. S2). The transduced bone marrow precursors were then transplanted into lethally irradiated recipient mice, which are referred to here as DLL1-mice and MigR1-mice. Thirteen weeks posttransplantation, we routinely observed 60% to 70% GFP-positive cells in peripheral blood cells, confirming successful transduction and reconstitution (data not shown). We then inoculated MigR1-mice or DLL1-mice with D459 tumor cells 8 weeks after bone marrow transplantation. We observed a remarkable inhibition of tumor growth in DLL1-mice compared with MigR1-mice (Fig. 2A). This inhibition was evident as early as day 21, and the tumor size remained nearly unchanged through day 35 (Fig. 2A). These data show that overexpressing DLL1 alone significantly inhibits tumor growth.

Notch signaling is known to play a critical role in T- versus B-cell fate decisions, and both DLL1 and DLL4 can promote T-cell development (3, 4). We have previously shown that tumor-derived factors inhibit T-lymphocyte development and
function (25, 26); thus, we hypothesized that reduced tumor growth in DLL1-mice could be mediated by enhanced T-cell activity. We observed a significant decrease in the fraction of T cells as well as the T(CD3e)/B(CD19) ratios in the spleens of MigR1-mice inoculated with D459 tumors (Fig. 2B). Conversely, overexpression of DLL1 alone in bone marrow precursors rescued these T-cell alterations, as tumor-bearing DLL1 animals showed no significant decrease in the proportion of splenic T cells and actually a significant increase in splenic T(CD3e)/B(CD19) ratios (Fig. 2B).

Production of IFN-γ is a critical indicator of Th1-type cytotoxic T-cell function that is important for antitumor immune responses. Upon anti-CD3 stimulation, we found that the number of IFN-γ–producing T cells (per 10^5 T cells) was dramatically increased in DLL1-mice bearing D459 tumors compared with MigR1-mice bearing D459 tumors (Fig. 2C). We also observed more tumor-infiltrating T cells in DLL1-mice than in MigR1-mice (data not shown). Importantly, these infiltrating T cells (and the peripheral blood T-cell fractions) had the same fractional GFP expression as did bulk circulating nucleated cells, suggesting that this was not a cell-autonomous effect (requiring DLL1 expression in the T cells themselves) but rather a consequence of increased expression in the hematopoietic environment in which they develop (data not shown). Together, our data suggest that overexpressing DLL1 alone significantly enhances T-cell immune responses and inhibits tumor growth.

**Elevated circulating VEGF inhibits T-cell development by downregulating the levels of DLL1 and DLL4 in the hematopoietic environment**

Higher levels of serum VEGF have been reported in patients with many types of cancers, such as non–small cell lung cancer (32). In animal models, circulating VEGF has been found to be derived not only from tumor cells but also from stromal cells, such as immune cells and endothelial cells (33, 34).
We have previously shown that elevated circulating VEGF alters host hematopoiesis including the inhibition of T lymphopoiesis (26). We therefore hypothesized that VEGF is one of the mediators to inhibit the expression of DLL1 and DLL4 in tumor-bearing hosts. As we observed in tumor-bearing mice, we found that transcriptional levels of DLL1 and DLL4 in bone marrow cells of non-tumor-bearing mice were significantly decreased in mice infused with recombinant VEGF at levels observed in tumor-bearing mice (Fig. 3A). Simultaneous administration of a VEGFR-2–specific antibody (DC101) reversed this effect (Fig. 3A). Expression of DLL1 and DLL4 protein in splenocytes was also dramatically decreased in VEGF-infused mice as was seen in tumor-bearing animals, and again DC101 treatment reversed this effect (Fig 3B). Similarly, a VEGFR-2 but not a VEGFR-1–specific ligand dramatically decreased expression of DLL1 and DLL4 proteins in the spleen (Fig. 3B). Together, these data indicate that VEGFR-2 signaling decreases the levels of DLL1 and DLL4 in the hematopoietic environment, consistent with the effects observed in tumor-bearing mice.

In experiments designed to determine whether lower levels of DLL1 and DLL4 in the bone marrow microenvironment altered Notch signaling, we found that transcriptional levels of Hes1 and Deltex1 (Notch target genes) were significantly decreased in VEGF-infused mice compared with those of PBS-infused mice (Fig. 3C) and DC101 treatment totally reversed this effect. We then implanted osmotic pumps containing recombinant VEGF or PBS diluted into MigR1-mice and DLL1-mice. The T-cell data from spleen and thymus indicate that overexpressing DLL1 alone overcomes the inhibition of VEGF on T-cell development (Fig. 4). Collectively, our data show that elevated circulating VEGF inhibits T-cell development by downregulating the levels of DLL1 and DLL4 in the hematopoietic environment.

**Figure 4. Overexpressing DLL1 alone in bone marrow precursors prevents the suppression of VEGF on T-cell development.** MigR1-mice or DLL1-mice were given a continuous infusion of PBS or of rhVEGF (100 ng/h) over a period of 28 days. A, flow cytometric analysis of splenocytes expressed CD3e and CD19. The representative plots are shown from 3 experiments carried out. B, the averages of T/B ratios in spleen, which were calculated by dividing the fraction of CD3e by the fraction of CD19 (mean ± SEM, ***P < 0.01, n = 3–4, 4 independent experiments). C, flow cytometric analysis of thymocytes expressed CD4 and CD8a in CD3e− cells. The representative plots are shown from 3 experiments carried out. D, the percentage of the T-cell subtypes in thymus (mean ± SEM, n ≥ 3).

T cells contribute to the tumor growth inhibition induced by selectively activated DLL1-Notch signaling

We also developed a novel reagent we refer to as clustered DLL1, which is a complex of DLL1-Fc, anti-Fc antibody, and avidin. Activation of Notch receptor proteolytic cleavage and signaling requires a multivalent interaction between Notch-expressing cells and Notch ligands. Whereas soluble forms of Notch ligands including DLL1 act as inhibitors of Notch signaling, soluble clustered DLL1 acts as an activator of Notch receptors (ref. 27; Fig. 5A and Supplementary Fig. S3A). To determine its effect on tumor growth in vivo, we treated D459 tumor–bearing mice with soluble clustered DLL1 or anti-Fc antibody–avidin complex as control. Like DLL1 overexpression data shown in Fig. 2A, we observed the inhibition of tumor growth as early as day 20 and the tumor growth rate remained much slower through day 30 in the soluble clustered DLL1 treatment mice than in the control group (Fig. 5B). A similar effect was observed in a different tumor model of Lewis lung carcinoma in a different strain of mice (C57BL/6), showing that this effect is not model specific (Fig. 5C). Together, our data show that soluble clustered DLL1 treatment dramatically inhibits tumor growth.

We then analyzed the effects of soluble clustered DLL1 treatment on T-cell function. As observed for the DLL1 vector transduction in Fig. 2B and C, soluble clustered DLL1 treatment increases the transcriptional levels of Hes1 and Deltex1 (Notch target genes) in the bone marrow (Fig. 6A), prevents the decrease in the T-cell fraction in tumor-bearing animals (Supplementary Fig. S3B), and significantly improves T-cell function.
IFN-γ production (Fig. 6B). This suggests that DLL1 treatment improves T-cell immune responses.

To test the contribution of T cells in tumor growth inhibition (Figs. 2A and 5), we carried out 2 kinds of experiments in 2 different tumor models (Fig. 5). First, we implanted LLC in both immunocompetent C57BL/6 mice and immunodeficient Rag1−/− mice. Then, we treated these LLC tumor–bearing mice with soluble clustered DLL1 or anti-Fc antibody–avidin complex as control. Soluble clustered DLL1 treatment significantly inhibited tumor growth in C57BL/6 mice but did not affect LLC tumor growth in the immunodeficient syngeneic Rag1−/− mice (Fig. 5C). We also treated wild-type mice bearing D459 tumor with clustered DLL1-Fc together with anti-CD8 antibody. CD8 T-cell depletion in mice abrogated tumor growth inhibition induced by soluble clustered DLL1 treatment (Fig 5B). Together, our data suggest that CD8 T cells contribute to tumor growth inhibition induced by soluble clustered DLL1 treatment.

Discussion

Compelling evidence suggests that immune cells play an important role in the control of malignant tumor growth (35, 36). However, tumors circumvent this control by
interfering with the induction and function of these immune responses, both systemically and in the tumor microenvironment. Thus, a major challenge for cancer immunotherapy is to use advances in cellular and molecular immunology to develop strategies that effectively and safely augment antitumor immune responses (37).

In this study, we describe a novel observation that tumors can systemically suppress host T-cell development and function by decreased levels of DLL1 and DLL4 in the hematopoietic environments. Selective stimulation of DLL1-Notch signaling enhances host tumor immunosurveillance and dramatically inhibits tumor growth. Importantly, we developed a potential therapeutic strategy using soluble clustered DLL1 ligand, which selectively stimulates DLL1-Notch signaling, augments T-cell function, and inhibits tumor growth.

To evaluate the roles and elements of the immune system in the inhibition of tumor growth responding to DLL1-Notch signaling activation, we showed that soluble clustered DLL1 treatment inhibited LLC tumor growth in wild-type mice but not in syngeneic C57BL/6 Rag$^{-/-}$ mice. Both T and B cells are deficient in Rag$^{-/-}$ mice, and B cells have been reported to have protumor effects (38). Although B cells may be reduced upon DLL1 stimulation, we did not address the role of B cells in our study. In contrast, our data showed that depletion of CD8$^+$ T cells in vivo abrogated tumor growth inhibition induced by soluble clustered DLL1.

In non–tumor-bearing hosts, it is well established that Notch signaling plays essential roles in immune cell development and differentiation (3, 4). There are 2 functional classes of Notch ligands in mammals: the Jagged family and Delta-like family. There are different functional consequences of Notch signaling stimulated by Jagged family members and stimulated by Delta-like family members (39–41), but the exact function of each Notch ligand in T lymphopoiesis is still not fully understood. Both in vitro and in vivo experiments suggest that the functions of Jagged1 and Jagged2 do not seem to play an important role in lymphopoiesis (39, 42, 43).

On the contrary, there are abundant data supporting a specific role for the Delta family ligands in T lymphopoiesis. Stromal cell overexpression of DLL1 or DLL4 is sufficient to induce T-cell development and inhibit B-cell development in vitro, but stromal cells expressing Jagged1 do not (16, 17, 39). Consistent with these observations, our data showed that overexpressing DLL1 alone in bone marrow precursors promotes T-cell development while suppressing B-cell development (Fig. 4). The effects may be different depending on signal intensity as well, as relatively lower densities of Delta$^{1\mathrm{ex}}$-IgG enhanced the generation of both T and B precursor cells and
higher densities of Delta1ext-IgG prompted the development of T precursor cells but inhibited B precursor cell development (22).

Pharmacologic inhibitors of Notch signaling have similar effects to those we have observed with tumors and systemic VEGF infusion. Inhibition of Notch signaling by increasing concentrations of a presenilin1/2 inhibitor converted T-cell development to B-cell development from hematopoietic progenitor cells cultured on OP9-DLL1 (44). Reduced Notch signaling in vivo by long-term treatment with a γ-secretase inhibitor also caused thymic atrophy and decreased total thymocytes as well as T-cell subtypes in thymus (45).

All of these results indicate that stronger Notch signaling by Delta family ligands induces T-cell development and inhibits B-cell development, whereas reduction in Notch signaling inhibits T-cell development and favors B-cell differentiation. This is consistent with a causative relationship that we find in this study between the inhibition of T-cell development and decreased Notch signaling in tumor-bearing animals and VEGF-infused mice.

In contrast to the induction of DLL4 in tumor vasculature (9), we observed a striking reduction of DLL1 and DLL4 in the hematopoietic environment (Fig. 1 and Supplementary Fig. S1). The difference is certainly due to the different cell types and tissues studied—local effects on vascular endothelial cells versus systemic effects on the hematopoietic environments we studied here. Dynamic, temporally, and spatially regulated expression of the mouse Dlli gene in distinct tissues and cell types is frequently observed in embryonic development (46).

Although DLL4 shows substantial homology with DLL1, others also have shown that they have distinct functions and cannot completely substitute for each other (47). Heterozygous DLL4, but not DLL1, knockouts have a vascular embryonic lethal phenotype (5). Either DLL1 or DLL4 alone is sufficient to support T-cell development, but overexpression of DLL4, not DLL1, results in T-cell leukemia (14–17). Consistent with these reports, we did not observe ectopic T-cell development and T-cell leukemia in these DLL1-overexpressing mouse models during our experimental period. DLL4 thus potentially affects both vascular development and T-cell development, but DLL1 appears more selectively important for T-cell maturation. Currently, we have not dissected which Notch receptor mediates the effect of DLL1 in our models. Notch1 may mediate the restoration of T-cell development (12, 13), and Notch2 seems to mediate the improvement of T-cell function (48).

Tumors suppress expression of both DLL1 and DLL4 in the bone marrow and spleen and induce DLL4 in tumor-adjacent endothelial cells (7), reflecting the distinct and regional immunologic and vascular effects of Notch signaling. Our data suggest that selectively promoting DLL1-mediated signaling reverses T-cell-mediated immunosuppression while avoiding the promotion of tumor angiogenesis proposed for DLL4.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Eugene Oltz, Pierre Massion, and Claudio Mosse for the critical reading and suggestions; Juan Carlos Zúñiga-Pflücker (University of Toronto) for providing Mgr1 and Mgr-DLL1 constructs; and Warren S. Pear (University of Pennsylvania) and Xiaolan Chen for their technical assistance in bone marrow transplantation. The authors also thank ImClone Systems for providing the DC101 antibody and Genentech Inc. for providing rhVEGF and receptor-specific VEGF mutants.

Grant Support

This work was supported by grants CA76321 (D.P. Carbone), CA138923 and CA100562 (M.M. Dikov) and from the Vanderbilt Lung Cancer SPORE (CA90949). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 13, 2010; revised July 14, 2011; accepted August 3, 2011; published OnlineFirst August 8, 2011.

References

Huang et al.


Resuscitating Cancer Immunosurveillance: Selective Stimulation of DLL1-Notch Signaling in T cells Rescues T-cell Function and Inhibits Tumor Growth

Yuhui Huang, Luping Lin, Anil Shanker, et al.

Cancer Res  Published OnlineFirst August 8, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-4366

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2011/08/08/0008-5472.CAN-10-4366.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.